Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens
Identifieur interne : 00A320 ( Main/Exploration ); précédent : 00A319; suivant : 00A321Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens
Auteurs : T. Thigpen [Niger] ; G. Stuart ; A. Du Bois ; M. Friedlander ; K. Fujiwara ; J. P. Guastalla ; S. Kaye [Royaume-Uni] ; H. Kitchener ; G. Kristensen ; R. Mannel ; W. Meier ; B. Miller ; A. Poveda ; D. Provencher ; F. Stehman ; I. VergoteSource :
- Annals of Oncology [ 0923-7534 ] ; 2005-10.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
- Adjuvant chemotherapy, Bulk reduction, Carboplatin, Carcinoma, Celomic epithelial carcinoma, Chemotherapy, Cisplatin, Clin, Clin oncol, Clinical trial, Clinical trials, Comparator, Consensus statements, Cytoreduction, Cytoreductive surgery, Debulking, Epithelial, Figo, Gcig, Gynecol, Gynecol oncol, Gynecologic, Gynecologic cancer, Gynecologic oncology group study, Hazard ratio, Human, Interval debulking, Large trials, Major trials, Natl cancer inst, Obstet gynecol, Oncol, Oncology, Ovarian, Ovarian cancer, Ovarian carcinoma, Ovary, Ovary carcinoma, Overall survival, Paclitaxel, Pegylated liposomal doxorubicin, Progression, Progression therapy, Randomized, Randomized phase, Randomized trials, Regimen, Residual, Residual disease, Response rate, Sequential doublets, Standard approaches, Standard comparator, Standard comparator regimen, Standard regimen, Standards, Surgical, Surgical bulk reduction, Surgical cytoreduction, Survival advantage, Survival impact, Systemic therapy, Taxane, Unanimous answer, Unanimous consensus.
- Teeft :
- Adjuvant chemotherapy, Bulk reduction, Carboplatin, Carcinoma, Celomic epithelial carcinoma, Chemotherapy, Cisplatin, Clin, Clin oncol, Clinical trial, Clinical trials, Comparator, Consensus statements, Cytoreduction, Cytoreductive surgery, Debulking, Epithelial, Figo, Gcig, Gynecol, Gynecol oncol, Gynecologic, Gynecologic cancer, Gynecologic oncology group study, Hazard ratio, Interval debulking, Large trials, Major trials, Natl cancer inst, Obstet gynecol, Oncol, Oncology, Ovarian, Ovarian cancer, Ovarian carcinoma, Ovary, Overall survival, Paclitaxel, Pegylated liposomal doxorubicin, Progression, Progression therapy, Randomized, Randomized phase, Randomized trials, Regimen, Residual, Residual disease, Response rate, Sequential doublets, Standard approaches, Standard comparator, Standard comparator regimen, Standard regimen, Surgical, Surgical bulk reduction, Surgical cytoreduction, Survival advantage, Survival impact, Systemic therapy, Taxane, Unanimous answer, Unanimous consensus.
Url:
DOI: 10.1093/annonc/mdi962
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000B68
- to stream Istex, to step Curation: 000B68
- to stream Istex, to step Checkpoint: 001878
- to stream Main, to step Merge: 00AE86
- to stream PascalFrancis, to step Corpus: 004641
- to stream PascalFrancis, to step Curation: 001A54
- to stream PascalFrancis, to step Checkpoint: 004707
- to stream Main, to step Merge: 00B357
- to stream Main, to step Curation: 00A320
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens</title><author><name sortKey="Thigpen, T" sort="Thigpen, T" uniqKey="Thigpen T" first="T." last="Thigpen">T. Thigpen</name></author><author><name sortKey="Stuart, G" sort="Stuart, G" uniqKey="Stuart G" first="G." last="Stuart">G. Stuart</name></author><author><name sortKey="Du Bois, A" sort="Du Bois, A" uniqKey="Du Bois A" first="A." last="Du Bois">A. Du Bois</name></author><author><name sortKey="Friedlander, M" sort="Friedlander, M" uniqKey="Friedlander M" first="M." last="Friedlander">M. Friedlander</name></author><author><name sortKey="Fujiwara, K" sort="Fujiwara, K" uniqKey="Fujiwara K" first="K." last="Fujiwara">K. Fujiwara</name></author><author><name sortKey="Guastalla, J P" sort="Guastalla, J P" uniqKey="Guastalla J" first="J. P." last="Guastalla">J. P. Guastalla</name></author><author><name sortKey="Kaye, S" sort="Kaye, S" uniqKey="Kaye S" first="S." last="Kaye">S. Kaye</name></author><author><name sortKey="Kitchener, H" sort="Kitchener, H" uniqKey="Kitchener H" first="H." last="Kitchener">H. Kitchener</name></author><author><name sortKey="Kristensen, G" sort="Kristensen, G" uniqKey="Kristensen G" first="G." last="Kristensen">G. Kristensen</name></author><author><name sortKey="Mannel, R" sort="Mannel, R" uniqKey="Mannel R" first="R." last="Mannel">R. Mannel</name></author><author><name sortKey="Meier, W" sort="Meier, W" uniqKey="Meier W" first="W." last="Meier">W. Meier</name></author><author><name sortKey="Miller, B" sort="Miller, B" uniqKey="Miller B" first="B." last="Miller">B. Miller</name></author><author><name sortKey="Poveda, A" sort="Poveda, A" uniqKey="Poveda A" first="A." last="Poveda">A. Poveda</name></author><author><name sortKey="Provencher, D" sort="Provencher, D" uniqKey="Provencher D" first="D." last="Provencher">D. Provencher</name></author><author><name sortKey="Stehman, F" sort="Stehman, F" uniqKey="Stehman F" first="F." last="Stehman">F. Stehman</name></author><author><name sortKey="Vergote, I" sort="Vergote, I" uniqKey="Vergote I" first="I." last="Vergote">I. Vergote</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3EB060F5D7294302CF530E4FCA38039AD67AEB36</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1093/annonc/mdi962</idno><idno type="url">https://api.istex.fr/document/3EB060F5D7294302CF530E4FCA38039AD67AEB36/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000B68</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000B68</idno><idno type="wicri:Area/Istex/Curation">000B68</idno><idno type="wicri:Area/Istex/Checkpoint">001878</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001878</idno><idno type="wicri:doubleKey">0923-7534:2005:Thigpen T:clinical:trials:in</idno><idno type="wicri:Area/Main/Merge">00AE86</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:06-0013010</idno><idno type="wicri:Area/PascalFrancis/Corpus">004641</idno><idno type="wicri:Area/PascalFrancis/Curation">001A54</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">004707</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">004707</idno><idno type="wicri:doubleKey">0923-7534:2005:Thigpen T:clinical:trials:in</idno><idno type="wicri:Area/Main/Merge">00B357</idno><idno type="wicri:Area/Main/Curation">00A320</idno><idno type="wicri:Area/Main/Exploration">00A320</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens</title><author><name sortKey="Thigpen, T" sort="Thigpen, T" uniqKey="Thigpen T" first="T." last="Thigpen">T. Thigpen</name><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Niger</country><wicri:regionArea>Correspondence to: Dr T. Thigpen, Department of Medicine, Division of Oncology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MI 39216</wicri:regionArea><wicri:noRegion>MI 39216</wicri:noRegion></affiliation></author><author><name sortKey="Stuart, G" sort="Stuart, G" uniqKey="Stuart G" first="G." last="Stuart">G. Stuart</name><affiliation><wicri:noCountry code="no comma">NCIC-CTG (Canada);</wicri:noCountry></affiliation></author><author><name sortKey="Du Bois, A" sort="Du Bois, A" uniqKey="Du Bois A" first="A." last="Du Bois">A. Du Bois</name><affiliation><wicri:noCountry code="no comma">AGO-OVAR (Germany);</wicri:noCountry></affiliation></author><author><name sortKey="Friedlander, M" sort="Friedlander, M" uniqKey="Friedlander M" first="M." last="Friedlander">M. Friedlander</name><affiliation><wicri:noCountry code="no comma">ANZGOG (Australia–New Zealand);</wicri:noCountry></affiliation></author><author><name sortKey="Fujiwara, K" sort="Fujiwara, K" uniqKey="Fujiwara K" first="K." last="Fujiwara">K. Fujiwara</name><affiliation><wicri:noCountry code="no comma">JGOG (Japan);</wicri:noCountry></affiliation></author><author><name sortKey="Guastalla, J P" sort="Guastalla, J P" uniqKey="Guastalla J" first="J. P." last="Guastalla">J. P. Guastalla</name><affiliation><wicri:noCountry code="no comma">GINECO (France);</wicri:noCountry></affiliation></author><author><name sortKey="Kaye, S" sort="Kaye, S" uniqKey="Kaye S" first="S." last="Kaye">S. Kaye</name><affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">Royaume-Uni</country><wicri:regionArea>SGCTG (Scotland</wicri:regionArea></affiliation></author><author><name sortKey="Kitchener, H" sort="Kitchener, H" uniqKey="Kitchener H" first="H." last="Kitchener">H. Kitchener</name><affiliation><wicri:noCountry code="no comma">MRC/NCRI (UK);</wicri:noCountry></affiliation></author><author><name sortKey="Kristensen, G" sort="Kristensen, G" uniqKey="Kristensen G" first="G." last="Kristensen">G. Kristensen</name><affiliation><wicri:noCountry code="no comma">NSGO (Scandinavia);</wicri:noCountry></affiliation></author><author><name sortKey="Mannel, R" sort="Mannel, R" uniqKey="Mannel R" first="R." last="Mannel">R. Mannel</name><affiliation><wicri:noCountry code="no comma">GOG (USA);</wicri:noCountry></affiliation></author><author><name sortKey="Meier, W" sort="Meier, W" uniqKey="Meier W" first="W." last="Meier">W. Meier</name><affiliation><wicri:noCountry code="no comma">AGO-OVAR (Germany);</wicri:noCountry></affiliation></author><author><name sortKey="Miller, B" sort="Miller, B" uniqKey="Miller B" first="B." last="Miller">B. Miller</name><affiliation><wicri:noCountry code="no comma">RTOG (USA);</wicri:noCountry></affiliation></author><author><name sortKey="Poveda, A" sort="Poveda, A" uniqKey="Poveda A" first="A." last="Poveda">A. Poveda</name><affiliation><wicri:noCountry code="no comma">GEICO (Spain);</wicri:noCountry></affiliation></author><author><name sortKey="Provencher, D" sort="Provencher, D" uniqKey="Provencher D" first="D." last="Provencher">D. Provencher</name><affiliation><wicri:noCountry code="no comma">NCIC-CTG (Canada);</wicri:noCountry></affiliation></author><author><name sortKey="Stehman, F" sort="Stehman, F" uniqKey="Stehman F" first="F." last="Stehman">F. Stehman</name><affiliation><wicri:noCountry code="no comma">GOG (USA);</wicri:noCountry></affiliation></author><author><name sortKey="Vergote, I" sort="Vergote, I" uniqKey="Vergote I" first="I." last="Vergote">I. Vergote</name><affiliation><wicri:noCountry code="no comma">EORTC (Europe)</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Oncology</title><title level="j" type="abbrev">Ann Oncol</title><idno type="ISSN">0923-7534</idno><idno type="eISSN">1569-8041</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2005-10">2005-10</date><biblScope unit="volume">16</biblScope><biblScope unit="supplement">suppl_8</biblScope><biblScope unit="page" from="13">viii13</biblScope><biblScope unit="page" to="19">viii19</biblScope></imprint><idno type="ISSN">0923-7534</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0923-7534</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvant chemotherapy</term><term>Bulk reduction</term><term>Carboplatin</term><term>Carcinoma</term><term>Celomic epithelial carcinoma</term><term>Chemotherapy</term><term>Cisplatin</term><term>Clin</term><term>Clin oncol</term><term>Clinical trial</term><term>Clinical trials</term><term>Comparator</term><term>Consensus statements</term><term>Cytoreduction</term><term>Cytoreductive surgery</term><term>Debulking</term><term>Epithelial</term><term>Figo</term><term>Gcig</term><term>Gynecol</term><term>Gynecol oncol</term><term>Gynecologic</term><term>Gynecologic cancer</term><term>Gynecologic oncology group study</term><term>Hazard ratio</term><term>Human</term><term>Interval debulking</term><term>Large trials</term><term>Major trials</term><term>Natl cancer inst</term><term>Obstet gynecol</term><term>Oncol</term><term>Oncology</term><term>Ovarian</term><term>Ovarian cancer</term><term>Ovarian carcinoma</term><term>Ovary</term><term>Ovary carcinoma</term><term>Overall survival</term><term>Paclitaxel</term><term>Pegylated liposomal doxorubicin</term><term>Progression</term><term>Progression therapy</term><term>Randomized</term><term>Randomized phase</term><term>Randomized trials</term><term>Regimen</term><term>Residual</term><term>Residual disease</term><term>Response rate</term><term>Sequential doublets</term><term>Standard approaches</term><term>Standard comparator</term><term>Standard comparator regimen</term><term>Standard regimen</term><term>Standards</term><term>Surgical</term><term>Surgical bulk reduction</term><term>Surgical cytoreduction</term><term>Survival advantage</term><term>Survival impact</term><term>Systemic therapy</term><term>Taxane</term><term>Unanimous answer</term><term>Unanimous consensus</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Carcinome ovaire</term><term>Essai clinique</term><term>Homme</term><term>Norme</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Adjuvant chemotherapy</term><term>Bulk reduction</term><term>Carboplatin</term><term>Carcinoma</term><term>Celomic epithelial carcinoma</term><term>Chemotherapy</term><term>Cisplatin</term><term>Clin</term><term>Clin oncol</term><term>Clinical trial</term><term>Clinical trials</term><term>Comparator</term><term>Consensus statements</term><term>Cytoreduction</term><term>Cytoreductive surgery</term><term>Debulking</term><term>Epithelial</term><term>Figo</term><term>Gcig</term><term>Gynecol</term><term>Gynecol oncol</term><term>Gynecologic</term><term>Gynecologic cancer</term><term>Gynecologic oncology group study</term><term>Hazard ratio</term><term>Interval debulking</term><term>Large trials</term><term>Major trials</term><term>Natl cancer inst</term><term>Obstet gynecol</term><term>Oncol</term><term>Oncology</term><term>Ovarian</term><term>Ovarian cancer</term><term>Ovarian carcinoma</term><term>Ovary</term><term>Overall survival</term><term>Paclitaxel</term><term>Pegylated liposomal doxorubicin</term><term>Progression</term><term>Progression therapy</term><term>Randomized</term><term>Randomized phase</term><term>Randomized trials</term><term>Regimen</term><term>Residual</term><term>Residual disease</term><term>Response rate</term><term>Sequential doublets</term><term>Standard approaches</term><term>Standard comparator</term><term>Standard comparator regimen</term><term>Standard regimen</term><term>Surgical</term><term>Surgical bulk reduction</term><term>Surgical cytoreduction</term><term>Survival advantage</term><term>Survival impact</term><term>Systemic therapy</term><term>Taxane</term><term>Unanimous answer</term><term>Unanimous consensus</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term><term>Norme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader></TEI><affiliations><list><country><li>Niger</li><li>Royaume-Uni</li></country></list><tree><noCountry><name sortKey="Du Bois, A" sort="Du Bois, A" uniqKey="Du Bois A" first="A." last="Du Bois">A. Du Bois</name><name sortKey="Friedlander, M" sort="Friedlander, M" uniqKey="Friedlander M" first="M." last="Friedlander">M. Friedlander</name><name sortKey="Fujiwara, K" sort="Fujiwara, K" uniqKey="Fujiwara K" first="K." last="Fujiwara">K. Fujiwara</name><name sortKey="Guastalla, J P" sort="Guastalla, J P" uniqKey="Guastalla J" first="J. P." last="Guastalla">J. P. Guastalla</name><name sortKey="Kitchener, H" sort="Kitchener, H" uniqKey="Kitchener H" first="H." last="Kitchener">H. Kitchener</name><name sortKey="Kristensen, G" sort="Kristensen, G" uniqKey="Kristensen G" first="G." last="Kristensen">G. Kristensen</name><name sortKey="Mannel, R" sort="Mannel, R" uniqKey="Mannel R" first="R." last="Mannel">R. Mannel</name><name sortKey="Meier, W" sort="Meier, W" uniqKey="Meier W" first="W." last="Meier">W. Meier</name><name sortKey="Miller, B" sort="Miller, B" uniqKey="Miller B" first="B." last="Miller">B. Miller</name><name sortKey="Poveda, A" sort="Poveda, A" uniqKey="Poveda A" first="A." last="Poveda">A. Poveda</name><name sortKey="Provencher, D" sort="Provencher, D" uniqKey="Provencher D" first="D." last="Provencher">D. Provencher</name><name sortKey="Stehman, F" sort="Stehman, F" uniqKey="Stehman F" first="F." last="Stehman">F. Stehman</name><name sortKey="Stuart, G" sort="Stuart, G" uniqKey="Stuart G" first="G." last="Stuart">G. Stuart</name><name sortKey="Vergote, I" sort="Vergote, I" uniqKey="Vergote I" first="I." last="Vergote">I. Vergote</name></noCountry><country name="Niger"><noRegion><name sortKey="Thigpen, T" sort="Thigpen, T" uniqKey="Thigpen T" first="T." last="Thigpen">T. Thigpen</name></noRegion></country><country name="Royaume-Uni"><noRegion><name sortKey="Kaye, S" sort="Kaye, S" uniqKey="Kaye S" first="S." last="Kaye">S. Kaye</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00A320 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00A320 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:3EB060F5D7294302CF530E4FCA38039AD67AEB36
|texte= Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens
}}
| This area was generated with Dilib version V0.6.33. |  |